Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of bezafibrate plus obeticholic acid vs bezafibrate in primary biliary cholangitis
2022-001241-20Phase 2Active
- Sponsor
- Intercept Pharmaceuticals
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Bezafibrate alone with Bezafibrate + obeticholic acid (2 arms). Primary endpoint: Change in alkaline phosphatase from baseline to Week 12. Started Sep 2022; status: active.
02
Drugs
bezafibrateobeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2022-001241-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001241-20.